A review of disease-modifying therapies for MS: maximizing adherence and minimizing adverse events

Author： Brandes David W.   Callender Teri   Lathi Ellen   O’Leary Shirley  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.25, Iss.1, 2009-01, pp. : 77-92

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison

By Hutchinson Michael   Fox Robert J.   Havrdova Eva   Kurukulasuriya Nuwan C.   Sarda Sujata P.   Agarwal Sonalee   Siddiqui Mohd Kashif   Taneja Ankush   Deniz Baris  

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 613-627

Informa Healthcare

Access to resources Recommend Favorite

Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis

By Moses Harold   Brandes David W.  

Current Medical Research and Opinion, Vol. 24, Iss. 9, 2008-09 ,pp. : 2679-2690

Informa Healthcare

Access to resources Recommend Favorite

Opioids: maximizing efficacy, minimizing adverse effects

By Smith Howard S  

Therapy, Vol. 6, Iss. 5, 2009-09 ,pp. : 629-631

Future Medicine

Access to resources Recommend Favorite

Disease-modifying drugs in multiple sclerosis: a review of expenditure in Ireland

By Bailey B.  

Irish Journal of Medical Science, Vol. 180, Iss. 2, 2011-06 ,pp. : 337-341

Springer Publishing Company

Access to resources Recommend Favorite

Disease‐modifying treatments for multiple sclerosis – a review of approved medications

By  

EUROPEAN JOURNAL OF NEUROLOGY, Vol. 23, Iss. S1, 2016-01 ,pp. : 18-27

John Wiley & Sons Inc

Access to resources Recommend Favorite